Today's Dead Cat Bounce Stock Is Supernus Pharmaceuticals (SUPN)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Supernus Pharmaceuticals ( SUPN) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Supernus Pharmaceuticals as such a stock due to the following factors:

  • SUPN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $36.9 million.
  • SUPN has traded 145,987 shares today.
  • SUPN is up 3.6% today.
  • SUPN was down 5.3% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SUPN with the Ticky from Trade-Ideas. See the FREE profile for SUPN NOW at Trade-Ideas

More details on SUPN:

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. SUPN has a PE ratio of 23. Currently there are 5 analysts that rate Supernus Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Supernus Pharmaceuticals has been 981,300 shares per day over the past 30 days. Supernus has a market cap of $807.2 million and is part of the health care sector and drugs industry. The stock has a beta of 0.81 and a short float of 6.4% with 0.98 days to cover. Shares are up 103.6% year-to-date as of the close of trading on Wednesday.

If you liked this article you might like

MediWound Shares Lower After Pricing Stock Offering - Biotech Movers

UPS, McKesson, Chegg and More: 'Mad Money' Lightning Round

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Anika Up on Strong Analyst Ratings